This review intends to provide guidance regarding perioperative management of anticoagulation and antiplatelet drug therapy as they relate to foot and ankle surgery. Venous and arterial thromboembolism are conditions in which the blood clots inappropriately, causing considerable morbidity and mortality. With an increase in awareness of thromboembolic risk factors and expansion of therapeutic options, more patients are routinely taking antithrombotic medication. When these patients require invasive procedures, a decision needs to be made if antithrombotic medication should be held perioperatively and if additional precautions are needed in the interim. Understanding the factors affecting the management of thromboembolism during the perioperative period can reduce the potential for complications.
Levels of Evidence: Therapeutic, Level V: Expert opinion
FreedmanJELoscalzoJ. Arterial and venous thrombosis. In: LongoDLFauciASKasperDLHauserSLJamesonJLLoscalzoJ, eds. Harrison’s Principles of Internal Medicine. 18th ed.New York, NY: McGraw-Hill; 2012:983-988.
2.
HartRGPearceLAAguilarMI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
3.
FurieKLKasnerSEAdamsRJ; American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227-276.
4.
FurieKLGoldsteinLBAlbersGW; American Heart Association Stroke Council; Council on Quality of Care and Outcomes Research; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:3442-3453.
5.
RadovanovicIQueallyJBahariSSprouleJMcElwainJ. Anticoagulant use and its effect on bleeding and complications in total knee arthroplasty. Acta Orthop Belg. 2012;78:187-191.
6.
DavieEWFujikawaKKisielW. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry. 1991;30:10363-10370.
7.
BeckmanMGHooperWCCritchleySEOrtelTL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(4 suppl):S495-S501.
8.
DubinASuenETDelaneyRChiuAJohnsonBC. Regulation of vitamin K-dependent carboxylation. J Biol Chem. 1980;255:349-352.
WelleMK. Understanding the new emerging oral anticoagulants for venous thromboembolism prophylaxis. Orthop Nurs. 2012;31:265-278.
13.
TsiaraSPappasKBoutsisDLaffanM. New oral anticoagulants: should they replace heparins and warfarin?Hellenic J Cardiol. 2011;52:52-57.
14.
US Food and Drug Administration. FDA Drug Safety Communication: update on the risk for serious bleeding events with the anticoagulant Pradaxa (dabigatran). http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm. Accessed June 26, 2013.
BudnitzDSLovegroveMCShehabNRichardsCL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002-2012.
18.
DouketisJDJohnsonJATurpieAG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med. 2004;164:1319-1326.
19.
KakkarVVDjazaeriBFokJFletcherMScullyMFWestwickJ. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. BMJ (Clin Res Ed). 1982;284:375-379.
20.
RupprechtHJBlankR. Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs. 2010;70:2153-2170.
21.
BaughmanRAKapoorSCAgarwalRKKisickiJCatella-LawsonFFitzGeraldGA. Oral delivery of anticoagulant doses of heparin: a randomized, double-blind controlled study in humans. Circulation. 1998;98:1610-1615.
22.
BurchJWStanfordNMajerusPW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest. 1978;61:314-319.
Effient [package insert]. Indianapolis, IN: Daiichi Sankyo and Eli Lilly; 2012.
25.
Brilinta [package insert]. Wilmington, DE: AstraZeneca LP; 2013.
26.
Pletal [package insert]. Rockville, MD: Otsuka American Pharmaceuticals; 2007.
27.
WeitzJIEikelboomJWSamamaMM. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e120S-e151S.
28.
GalatDDMcGovernSCHanssenADLarsonDRHarringtonJRClarkeHD. Early return to surgery for evacuation of a postoperative hematoma after primary total knee arthroplasty. J Bone Joint Surg Am. 2008;90:2331-2336.
GallegoPApostolakisSLipGY. Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. Circulation. 2012;126:1573-1576.
31.
ApostolakisSLaneDAGuoYBullerHLipGY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk–prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) Study. J Am Coll Cardiol. 2012;60:861-867.
32.
HentgesMJPetersonKSCatanzaritiARMendicinoRW. Venous thromboembolism and foot and ankle surgery: current updates 2012. Foot Ankle Spec. 2012;5:401-407.
33.
SlaybaughRSBeasleyBDMassaEG. Deep venous thrombosis risk assessment, incidence, and prophylaxis in foot and ankle surgery. Clin Podiatr Med Surg. 2003;20:269-289.
34.
DouketisJDSpyropoulosACSpencerFA. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guideline. Chest. 2012;141:e326S-e350S.
35.
National Institutes of Health Clinical Center. A safety and effectiveness study of LMWH bridging therapy versus placebo bridging therapy for patients on long term warfarin and require temporary interruption of their warfarin (PERIOP2). ClinicalTrials.gov Web site NCT00432796.
36.
National Institutes of Health Clinical Center. Effectiveness of Bridging Anticoagulation for Surgery (the BRIDGE Study). ClinicalTrials.gov Web site NCT00786474.
37.
Canadian Institutes of Health Research. Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial (BRUISECONTROL). ClinicalTrials.gov Web site NCT00800137.
38.
ThakurNACzerweinJKButeraJNPalumboMA. Perioperative management of chronic anticoagulation in orthopaedic surgery. J Am Acad Orthop Surg. 2010;18:729-738.
39.
HannaClStreiffMB. Vena caval filters: a comprehensive review. Blood. 2000;95:3669-3677.
40.
KinneyTBPankoJEFunakiBS; Expert Panel on Interventional Radiology. ACR Appropriateness Criteria® radiologic management of inferior vena cava filters [online publication]. Reston, VA: American College of Radiology; 2009. http://www.guideline.gov/content.aspx?id=15730. Accessed June 26, 2013.
41.
GouldMKGarciaDAWrenSM; American College of Chest Physicians. Prevention of VTE in nonorthopedic surgical patients. Chest. 2012;141:e227S-e277S.
AgenoWGallusASWittkowskyACrowtherMHylekEMPalaretiG. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S-e88S.
45.
GarciaDABaglinTPWeitzJISamamaMM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guideline. Chest. 2012;141:e24S-e43S.
46.
NutescuEA. Oral anticoagulant therapies: balancing the risks. Am J Health Syst Pharm. 2013;70(10 suppl 1):S3-S11.
47.
KambojJKottalgiMCirraVRShahNKambojR. Direct thrombin inhibitors: a case indicating benefit from “plasmapheresis” in toxicity: a call for establishing “guidelines” in overdose and to find an “antidote”!Am J Ther. 2012;19:e182-e185.
48.
PernodGAlbaladejoPGodierA. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the Working Group on Perioperative Haemostasis (GIHP)—March 2013. Arch Cardiovasc Dis. 2013;106:382-393.
49.
BaglinTHillarpATripodiAElalamyIBullerHAgenoW. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013;11:756-760.
50.
CrowtherMAWarkentinTE. Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost. 2009;7(suppl 1):107-110.
51.
FawoleADawHACrowtherMA. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med. 2013;80:443-451.
52.
Baumann KreuzigerLMRedingMT. Management of bleeding associated with Dabigatran and Rivaroxaban: a survey of current practices. Thromb Res. 2013;32:e161-e163.
53.
WannLSCurtisABEllenbogenKA. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011;57:1330-1337.
54.
Nitzki-GeorgeDWozniakICapriniJA. Current state of knowledge on oral anticoagulant reversal using procoagulant factors. Ann Pharmacother. 2013;47:841-855.
55.
EsnaultPGaillardPECotteJCungiPJBeaumeJPrunetB. Haemodialysis before emergency surgery in a patient treated with dabigatran. Br J Anaesth. 2013;111:776-777.
56.
SteeleMJFoxJSFletcherJPGriggLEBellG. Clopidogrel dilemma for orthopaedic surgeons. ANZ J Surg. 2011;81:774-784.
57.
FinkelJBMarhefkaGDWeitzHH. Dual antiplatelet therapy with aspirin and clopidogrel: what is the risk in noncardiac surgery? A narrative review. Hosp Pract. 2013;41:79-88.
58.
Di MinnoMNPriscoDRuoccoALMastronardiPMassaSDi MinnoG. Perioperative handling of patients on antiplatelet therapy with need for surgery. Intern Emerg Med. 2009;4:279-288.
59.
SkolnickBEShenoudaMKhutoryanskyNMPusateriAEGabrielDCarrME. Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. Anesth Analg. 2011;113:703-710.
60.
KarkoutiKLevyJH. Recombinant activated factor VII: the controversial conundrum regarding its off-label use. Anesth Analg. 2012;115:364-378.
61.
LlauJVFerrandisR. New anticoagulants and regional anesthesia. Curr Opin Anaesthesiol. 2009;22:661-666.
62.
HeidbuchelHVerhammePAlingsM. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625-651.
63.
LarsonBJZumbergMSKitchensCS. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk. Chest. 2005;127:922-927.
64.
FlaniganDCMuchowROrwinJGrafB. Arthroscopy on anticoagulated patients: a retrospective evaluation of postoperative complications. Orthopedics. 2010;33:82-86.
65.
SørensenRHansenMLAbildstromSZ. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967-1974.
66.
HolmesDRJrKereiakesDJKleimanNSMoliternoDJPattiGGrinesCL. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol. 2009;54:95-109.
67.
StangerMJThompsonLAYoungAJLiebermanHR. Anticoagulant activity of select dietary supplements. Nutr Rev. 2012;70:107-117.
68.
HylekEM. Dabigatran and mechanical heart valves—not as easy as we hoped. N Engl J Med. 2013;369:1264-1266.
69.
FerrandisRCastilloJde AndrésJ. The perioperative management of new direct oral anticoagulants: a question without answers. Thromb Haemost. 2012;110:515-522.
